{"id":820327,"date":"2025-03-03T06:35:45","date_gmt":"2025-03-03T11:35:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/"},"modified":"2025-03-03T06:35:45","modified_gmt":"2025-03-03T11:35:45","slug":"immunic-to-participate-in-scientific-and-investor-conferences-in-march","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/","title":{"rendered":"Immunic to Participate in Scientific and Investor Conferences in March"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 3, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<b><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4370843-1&amp;h=1131306022&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.\" target=\"_blank\" rel=\"nofollow\">Immunic, Inc.<\/a><\/b>\u00a0(Nasdaq: IMUX),\u00a0a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March:<\/p>\n<ul type=\"disc\">\n<li>\n          <span class=\"xn-chron\">March 4-7<\/span>:<b> 34<sup>th<\/sup> Annual Meeting of the Society for Virology. <\/b>Two abstracts have been accepted for abstract talk presentations at this conference in <span class=\"xn-location\">Hamburg, Germany<\/span>. The presentations will be accessible on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4370843-1&amp;h=2989379562&amp;u=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations\" target=\"_blank\" rel=\"nofollow\">https:\/\/ir.imux.com\/events-and-presentations<\/a>.<\/p>\n<ul type=\"disc\">\n<li><b>Title:<\/b>\u00a0<i>Orally Bioavailable ROR\u03b3\/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity<\/i><\/li>\n<li><b>Presenting Author: <\/b><span class=\"xn-person\">Friedrich Hahn<\/span>, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, <span class=\"xn-location\">Germany<\/span><\/li>\n<li><b>Abstract Talk:<\/b>\u00a0O 081<\/li>\n<li><b>Session:<\/b>\u00a0Antiviral therapy and resistance I<\/li>\n<li><b>Date: <\/b><span class=\"xn-chron\">March 6, 2025<\/span><\/li>\n<li><b>Time: <\/b>9:30-9:45 am\u00a0CET (<span class=\"xn-chron\">3:30-3:45am ET<\/span>)\n<\/li>\n<li><b>Title:<\/b>\u00a0<i>Novel Vidofludimus-Based DHODH Inhibitors Containing Carboxylic Acid Bioisosters with Superior Broad-Spectrum Antiviral Activity<\/i><\/li>\n<li><b>Presenting Author: <\/b><span class=\"xn-person\">Alexandra Herrmann<\/span>, Ph.D., Manager Translational Pharmacology, Immunic<\/li>\n<li><b>Abstract Talk:<\/b>\u00a0O 112<\/li>\n<li><b>Session:<\/b>\u00a0Antiviral therapy and resistance II<\/li>\n<li><b>Date: <\/b><span class=\"xn-chron\">March 7, 2025<\/span><\/li>\n<li><b>Time: <\/b><span class=\"xn-chron\">11:00-11:15am CET<\/span> (<span class=\"xn-chron\">5:00-5:15am ET<\/span>)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <span class=\"xn-chron\">March 10-12<\/span>: <b>Leerink Partners Global Healthcare Conference. <\/b><span class=\"xn-person\">Daniel Vitt<\/span>, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on <span class=\"xn-chron\">Wednesday, March 12<\/span>, at <span class=\"xn-chron\">10:00 am ET<\/span> during this conference in <span class=\"xn-location\">Miami<\/span>. A webcast will be available on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4370843-1&amp;h=2989379562&amp;u=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations\" target=\"_blank\" rel=\"nofollow\">https:\/\/ir.imux.com\/events-and-presentations<\/a>.<\/p>\n<p>Dr. Vitt, <span class=\"xn-person\">Glenn Whaley<\/span>, Chief Financial Officer, and <span class=\"xn-person\">Jessica Breu<\/span>, Vice President Investor Relations and Communications, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or <span class=\"xn-person\">Jessica Breu<\/span> at: <a href=\"mailto:jessica.breu@imux.com\" target=\"_blank\" rel=\"nofollow\">jessica.breu@imux.com<\/a>.<\/li>\n<\/ul>\n<p>\n        <b>About Immunic, Inc.<br \/><\/b>Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company&#8217;s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease,\u00a0Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4370843-1&amp;h=2297065379&amp;u=http%3A%2F%2Fwww.imux.com%2F&amp;a=www.imux.com\" target=\"_blank\" rel=\"nofollow\">www.imux.com<\/a>.<\/p>\n<p>\n        <b>Cautionary Statement Regarding Forward-Looking Statements<br \/><\/b>This press release contains &#8220;forward-looking statements&#8221; that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management&#8217;s and employee&#8217;s participation in scientific and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management&#8217;s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the <span class=\"xn-location\">Ukraine<\/span> \u2013 <span class=\"xn-location\">Russia<\/span> conflict and the conflict in the <span class=\"xn-location\">Middle East<\/span> on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the <span class=\"xn-chron\">January 2024<\/span> private placement, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company&#8217;s products or product candidates, the protection and market exclusivity provided by Immunic&#8217;s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned &#8220;Risk Factors,&#8221; in the company&#8217;s Annual Report on Form 10-K for the fiscal year ended <span class=\"xn-chron\">December 31, 2023<\/span>, filed with the SEC on <span class=\"xn-chron\">February 22, 2024<\/span>, and in the company&#8217;s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at <a href=\"http:\/\/www.sec.gov\" rel=\"nofollow\">www.sec.gov<\/a> or ir.imux.com\/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.<\/p>\n<p>\n        <b>Contact Information<\/b>\n      <\/p>\n<p>\n        <b>Immunic, Inc.<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Jessica Breu<\/span><br \/>\n        <br \/>Vice President Investor Relations and Communications<br \/>+49 89 2080 477 09<br \/><a href=\"mailto:jessica.breu@imux.com\" target=\"_blank\" rel=\"nofollow\">jessica.breu@imux.com<\/a><\/p>\n<p>\n        <b>US IR Contact<\/b><br \/>\n        <br \/>Rx Communications Group<br \/><span class=\"xn-person\">Paula Schwartz<\/span><br \/>+1 917 633 7790<br \/><a href=\"mailto:immunic@rxir.com\" target=\"_blank\" rel=\"nofollow\">immunic@rxir.com<\/a><\/p>\n<p>\n        <b>US Media Contact<\/b><br \/>\n        <br \/>KCSA Strategic Communications<br \/><span class=\"xn-person\">Caitlin Kasunich<\/span><br \/>+1 212 896 1241<br \/><a href=\"mailto:ckasunich@kcsa.com\" target=\"_blank\" rel=\"nofollow\">ckasunich@kcsa.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3951\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg\" title=\"Immunic, Inc. Logo (PRNewsfoto\/Immunic, Inc.)\" alt=\"Immunic, Inc. Logo (PRNewsfoto\/Immunic, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY27935&amp;sd=2025-03-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/immunic-to-participate-in-scientific-and-investor-conferences-in-march-302386106.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/immunic-to-participate-in-scientific-and-investor-conferences-in-march-302386106.html<\/a><\/p>\n<p>SOURCE  Immunic, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY27935&amp;Transmission_Id=202503030630PR_NEWS_USPR_____NY27935&amp;DateId=20250303\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , March 3, 2025 \/PRNewswire\/ &#8212;\u00a0Immunic, Inc.\u00a0(Nasdaq: IMUX),\u00a0a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: https:\/\/ir.imux.com\/events-and-presentations. Title:\u00a0Orally Bioavailable ROR\u03b3\/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Germany Abstract Talk:\u00a0O 081 Session:\u00a0Antiviral therapy and resistance I Date: March 6, 2025 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immunic to Participate in Scientific and Investor Conferences in March&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-820327","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunic to Participate in Scientific and Investor Conferences in March - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunic to Participate in Scientific and Investor Conferences in March - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , March 3, 2025 \/PRNewswire\/ &#8212;\u00a0Immunic, Inc.\u00a0(Nasdaq: IMUX),\u00a0a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: https:\/\/ir.imux.com\/events-and-presentations. Title:\u00a0Orally Bioavailable ROR\u03b3\/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Germany Abstract Talk:\u00a0O 081 Session:\u00a0Antiviral therapy and resistance I Date: March 6, 2025 &hellip; Continue reading &quot;Immunic to Participate in Scientific and Investor Conferences in March&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T11:35:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunic to Participate in Scientific and Investor Conferences in March\",\"datePublished\":\"2025-03-03T11:35:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/\"},\"wordCount\":973,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/\",\"name\":\"Immunic to Participate in Scientific and Investor Conferences in March - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"datePublished\":\"2025-03-03T11:35:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunic to Participate in Scientific and Investor Conferences in March\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunic to Participate in Scientific and Investor Conferences in March - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/","og_locale":"en_US","og_type":"article","og_title":"Immunic to Participate in Scientific and Investor Conferences in March - Market Newsdesk","og_description":"PR Newswire NEW YORK , March 3, 2025 \/PRNewswire\/ &#8212;\u00a0Immunic, Inc.\u00a0(Nasdaq: IMUX),\u00a0a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: https:\/\/ir.imux.com\/events-and-presentations. Title:\u00a0Orally Bioavailable ROR\u03b3\/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Germany Abstract Talk:\u00a0O 081 Session:\u00a0Antiviral therapy and resistance I Date: March 6, 2025 &hellip; Continue reading \"Immunic to Participate in Scientific and Investor Conferences in March\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-03T11:35:45+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunic to Participate in Scientific and Investor Conferences in March","datePublished":"2025-03-03T11:35:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/"},"wordCount":973,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/","name":"Immunic to Participate in Scientific and Investor Conferences in March - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","datePublished":"2025-03-03T11:35:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-scientific-and-investor-conferences-in-march\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunic to Participate in Scientific and Investor Conferences in March"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=820327"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820327\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=820327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=820327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=820327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}